Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Irritable Bowel Syndrome HELP
Based on 4,531 articles published since 2007

These are the 4531 published articles about Irritable Bowel Syndrome that originated from Worldwide during 2007-2017.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Pharmacologic Management of Irritable Bowel Syndrome. 2015

Rao, Vijaya L / Cifu, Adam S / Yang, Leslie W / Anonymous1300854. ·Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, Illinois. · Section of General Internal Medicine, University of Chicago Medical Center, Chicago, Illinois. · ·JAMA · Pubmed #26720029.

ABSTRACT: -- No abstract --

2 Guideline Evidence-based clinical practice guidelines for irritable bowel syndrome. 2015

Fukudo, Shin / Kaneko, Hiroshi / Akiho, Hirotada / Inamori, Masahiko / Endo, Yuka / Okumura, Toshikatsu / Kanazawa, Motoyori / Kamiya, Takeshi / Sato, Ken / Chiba, Toshimi / Furuta, Kenji / Yamato, Shigeru / Arakawa, Tetsuo / Fujiyama, Yoshihide / Azuma, Takeshi / Fujimoto, Kazuma / Mine, Tetsuya / Miura, Soichiro / Kinoshita, Yoshikazu / Sugano, Kentaro / Shimosegawa, Tooru. ·Guidelines Committee for creating and evaluating the "Evidence-based clinical practice guidelines for irritable bowel syndrome", the Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13 Ginza, Chuo, Tokyo, 104-0061, Japan, sfukudo@med.tohoku.ac.jp. · ·J Gastroenterol · Pubmed #25500976.

ABSTRACT: New strategies for the care of irritable bowel syndrome (IBS) are developing and several novel treatments have been globally produced. New methods of care should be customized geographically because each country has a specific medical system, life style, eating habit, gut microbiota, genes and so on. Several clinical guidelines for IBS have been proposed and the Japanese Society of Gastroenterology (JSGE) subsequently developed evidence-based clinical practice guidelines for IBS. Sixty-two clinical questions (CQs) comprising 1 definition, 6 epidemiology, 6 pathophysiology, 10 diagnosis, 30 treatment, 4 prognosis, and 5 complications were proposed and statements were made to answer to CQs. A diagnosis algorithm and a three-step treatment was provided for patients with chronic abdominal pain or abdominal discomfort and/or abnormal bowel movement. If more than one alarm symptom/sign, risk factor and/or routine examination is positive, colonoscopy is indicated. If all of them, or the subsequent colonoscopy, are/is negative, Rome III or compatible criteria is applied. After IBS diagnosis, step 1 therapy consisting of diet therapy, behavioral modification and gut-targeted pharmacotherapy is indicated for four weeks. Non-responders to step 1 therapy proceed to the second step that includes psychopharmacological agents and simple psychotherapy for four weeks. In the third step, for patients non-responsive to step 2 therapy, a combination of gut-targeted pharmacotherapy, psychopharmacological treatments and/or specific psychotherapy is/are indicated. Clinical guidelines and consensus for IBS treatment in Japan are well suited for Japanese IBS patients; as such, they may provide useful insight for IBS treatment in other countries around the world.

3 Guideline The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. 2014

Dumitrascu, Dan L / Chira, Alexandra / Bataga, Simona / Diculescu, Mircea / Drug, Vasile / Gheorghe, Cristian / Goldis, Adrian / Nedelcu, Laurentiu / Porr, Paul J / Sporea, Ioan / Anonymous3090816. ·2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ddumitrascu@umfcluj.ro. · 2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · University of Medicine and Pharmacy, Tg-Mures, Romania. · Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. · Gr. T. Popa University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Iasi, Romania. · Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Timisoara, Romania. · Department of Internal Medicine, Transilvania University, Brasov, Romania. · Lucian Blaga University, Sibiu, Romania. · ·J Gastrointestin Liver Dis · Pubmed #25532003.

ABSTRACT: -- No abstract --

4 Guideline American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. 2014

Weinberg, David S / Smalley, Walter / Heidelbaugh, Joel J / Sultan, Shahnaz / Anonymous5610806. ·Fox Chase Cancer Center, Philadelphia, Pennsylvania. · VA Tennessee Valley Healthcare System, Vanderbilt University, Nashville, Tennessee. · University of Michigan Ann Arbor, Michigan. · Department of Veterans Affairs Medical Center, Gastroenterology Section, North Florida/South Georgia Veterans Health System, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida; Minneapolis Veterans Affairs Health System, University of Minnesota, Minneapolis, Minnesota. · ·Gastroenterology · Pubmed #25224526.

ABSTRACT: -- No abstract --

5 Guideline [Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)]. 2013

Andresen, V / Layer, P / Anonymous4950776 / Anonymous4960776 / Anonymous4970776. · ·Z Gastroenterol · Pubmed #24266047.

ABSTRACT: -- No abstract --

6 Guideline Intestinal microbiota in functional bowel disorders: a Rome foundation report. 2013

Simrén, Magnus / Barbara, Giovanni / Flint, Harry J / Spiegel, Brennan M R / Spiller, Robin C / Vanner, Stephen / Verdu, Elena F / Whorwell, Peter J / Zoetendal, Erwin G / Anonymous90730. ·Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg S-41345, Sweden. magnus.simren@medicine.gu.se · ·Gut · Pubmed #22730468.

ABSTRACT: It is increasingly perceived that gut host-microbial interactions are important elements in the pathogenesis of functional gastrointestinal disorders (FGID). The most convincing evidence to date is the finding that functional dyspepsia and irritable bowel syndrome (IBS) may develop in predisposed individuals following a bout of infectious gastroenteritis. There has been a great deal of interest in the potential clinical and therapeutic implications of small intestinal bacterial overgrowth in IBS. However, this theory has generated much debate because the evidence is largely based on breath tests which have not been validated. The introduction of culture-independent molecular techniques provides a major advancement in our understanding of the microbial community in FGID. Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS. Investigators are also starting to measure host-microbial interactions in IBS. The current working hypothesis is that abnormal microbiota activate mucosal innate immune responses which increase epithelial permeability, activate nociceptive sensory pathways and dysregulate the enteric nervous system. While we await important insights in this field, the microbiota is already a therapeutic target. Existing controlled trials of dietary manipulation, prebiotics, probiotics, synbiotics and non-absorbable antibiotics are promising, although most are limited by suboptimal design and small sample size. In this article, the authors provide a critical review of current hypotheses regarding the pathogenetic involvement of microbiota in FGID and evaluate the results of microbiota-directed interventions. The authors also provide clinical guidance on modulation of gut microbiota in IBS.

7 Guideline British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. 2012

McKenzie, Y A / Alder, A / Anderson, W / Wills, A / Goddard, L / Gulia, P / Jankovich, E / Mutch, P / Reeves, L B / Singer, A / Lomer, M C E / Anonymous1590723. ·Nuffield Health The Manor Hospital, Oxford, UK Department of Nutrition and Dietetics, Royal Sussex County Hospital, Brighton, UK. · ·J Hum Nutr Diet · Pubmed #22489905.

ABSTRACT: BACKGROUND:  Irritable bowel syndrome (IBS) is a chronic debilitating functional gastrointestinal disorder. Diet and lifestyle changes are important management strategies. The aim of these guidelines is to systematically review key aspects of the dietary management of IBS, with the aim of providing evidence-based guidelines for use by registered dietitians. METHODS: Questions relating to diet and IBS symptom management were developed by a guideline development group. These included the role of milk and lactose, nonstarch polysaccharides (NSP), fermentable carbohydrates in abdominal bloating, probiotics and empirical or elimination diets. A comprehensive literature search was conducted and relevant studies from January 1985 to November 2009 were identified using the electronic database search engines: Cinahl, Cochrane Library, Embase, Medline, Scopus and Web of Science. Evidence statements, recommendations, good practice points and research recommendations were developed. RESULTS: Thirty studies were critically appraised. A dietetic care pathway was produced following a logical sequence of treatment and formed the basis of these guidelines. Three lines of dietary management were identified. first line: Clinical and dietary assessment, healthy eating and lifestyle management with some general advice on lactose and NSP. Second line: Advanced dietary interventions to improve symptoms based on NSP, fermentable carbohydrates and probiotics. Third line: Elimination and empirical diets. Research recommendations were also identified relating to the need for adequately powered and well designed randomised controlled trials. CONCLUSIONS: These guidelines provide evidence-based details of how to achieve the successful dietary management of IBS.

8 Guideline [IBD ahead 2010--Answering important questions in Crohn's disease treatment]. 2011

Schmidt, C / Dignass, A / Hartmann, F / Hüppe, D / Kruis, W / Layer, P / Lüers, A / Stallmach, A / Teich, N / Sturm, A / Anonymous6650703. ·Universitätklinikum Jena, Klinik für Innere Medizin II, Abteilung für Gastroenterologie, Hepatologie und Infektiologie. · ·Z Gastroenterol · Pubmed #21866492.

ABSTRACT: The treatment of patients with inflammatory bowel disease has become more complex in recent years through the introduction of various immunosuppressive agents as well as the approval of monoclonal antibodies against TNF-α and patients receiving such treatment must be carefully monitored. National and international guidelines define a diagnostic and therapeutic context for the practitioner, but can only partially respond to specific questions on the procedure for individual patients. Within the framework of a project initiated by Abbott entitled "IBD ahead" 38 German IBD experts have elaborated concrete proposals for dealing with corticosteroids, immunosuppressants and TNF-α antibodies on the basis of the published literature and their own personal experience in order to close the gap between these guidelines and daily clinical practice. Statements were developed on the choice of correct timing of initiation, dose and duration of the individual substances and on how to proceed with patients exhibiting treatment failure. Moreover, recommendations are also made on drug combination strategies, safety monitoring and the risks regarding the development of infectious complications and malignancies. These recommendations are illustrated by case studies from everyday practice in participating centres.

9 Guideline [Guidelines for the treatment of irritable bowel syndrome]. 2011

Kwon, Joong Goo / Park, Kyung Sik / Park, Jung Ho / Park, Jae Myung / Park, Cheol Hee / Lee, Kwang Jae / Park, Hyo Jin / Rhee, Jong Chul / Anonymous561390. ·Department of Internal Medicine, Catholic University of Daegu School of Medicine, Korea. · ·Korean J Gastroenterol · Pubmed #21350320.

ABSTRACT: Traditional symptom-based therapies of irritable bowel syndrome (IBS) are directed at the relief of individual IBS symptoms, but they are often of limited efficacy in addressing the entire symptom complex. Combinations of drugs to target bothersome symptoms are suggested as the first-line pharmacologic treatment. Increasing knowledge of the pathophysiology and molecular mechanisms of IBS has resulted in the development of several new therapeutic approaches. Thirteen consensus statements for the treatment of IBS were developed using the modified Delphi approach. Exclusion diets have modest efficacy in improving symptoms in some IBS patients. Symptom-based therapies with dietary fiber, bulking agents, laxatives, antispasmodics and laxatives are effective in the improvement of some individual symptoms, e.g. dietary fiber and bulking agents for constipation, laxatives for constipation, antispasmodics for abdominal pain and discomfort, antidiarrheals for diarrhea. 5HT3 receptor antagonists and 5HT((4)) receptor agonists are effective in the relief of global IBS symptoms and individual symptoms such as abdominal pain and abnormal bowel habits. A short term course of nonabsorbable antibiotics may improve global IBS symptoms, particularly in patients with diarrhea- predominant IBS. Some probiotics appear to have the potential benefit in improving global IBS symptoms. Selective C-2 chloride channel activator is more effective than placebo at relieving global IBS symptoms in patients with constipation-predominant IBS. Both tricyclic antidepressants and selective serotonin reuptake inhibitors are equally effective in relieving global IBS symptoms, and have some benefits in treating abdominal pain. Certain types of psychologic therapy may be effective in improving global symptoms in some IBS patients. Further studies are strongly needed to develop better treatment strategies for Korean patients with IBS.

10 Guideline [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. 2011

Layer, P / Andresen, V / Pehl, C / Allescher, H / Bischoff, S C / Classen, M / Enck, P / Frieling, T / Haag, S / Holtmann, G / Karaus, M / Kathemann, S / Keller, J / Kuhlbusch-Zicklam, R / Kruis, W / Langhorst, J / Matthes, H / Mönnikes, H / Müller-Lissner, S / Musial, F / Otto, B / Rosenberger, C / Schemann, M / van der Voort, I / Dathe, K / Preiss, J C / Anonymous5980685 / Anonymous5990685. ·Für die Konsensusgruppe Reizdarmsyndrom; Konsensuskonferenz 18./ 19.9.2009. layer@ik-h.de · ·Z Gastroenterol · Pubmed #21287438.

ABSTRACT: -- No abstract --

11 Guideline Asian consensus on irritable bowel syndrome. 2010

Gwee, Kok-Ann / Bak, Young-Tae / Ghoshal, Uday Chand / Gonlachanvit, Sutep / Lee, Oh Young / Fock, Kwong Ming / Chua, Andrew Seng Boon / Lu, Ching-Liang / Goh, Khean-Lee / Kositchaiwat, Chomsri / Makharia, Govind / Park, Hyo-Jin / Chang, Full-Young / Fukudo, Shin / Choi, Myung-Gyu / Bhatia, Shobna / Ke, Meiyun / Hou, Xiaohua / Hongo, Michio / Anonymous6490664. ·Stomach Liver and Bowel Clinic, Gleneagles Hospital, Singapore. slbclinic@gmail.com · ·J Gastroenterol Hepatol · Pubmed #20594245.

ABSTRACT: BACKGROUND AND AIMS: Many of the ideas on irritable bowel syndrome (IBS) are derived from studies conducted in Western societies. Their relevance to Asian societies has not been critically examined. Our objectives were to bring to attention important data from Asian studies, articulate the experience and views of our Asian experts, and provide a relevant guide on this poorly understood condition for doctors and scientists working in Asia. METHODS: A multinational group of physicians from Asia with special interest in IBS raised statements on IBS pertaining to symptoms, diagnosis, epidemiology, infection, pathophysiology, motility, management, and diet. A modified Delphi approach was employed to present and grade the quality of evidence, and determine the level of agreement. RESULTS: We observed that bloating and symptoms associated with meals were prominent complaints among our IBS patients. In the majority of our countries, we did not observe a female predominance. In some Asian populations, the intestinal transit times in healthy and IBS patients appear to be faster than those reported in the West. High consultation rates were observed, particularly in the more affluent countries. There was only weak evidence to support the perception that psychological distress determines health-care seeking. Dietary factors, in particular, chili consumption and the high prevalence of lactose malabsorption, were perceived to be aggravating factors, but the evidence was weak. CONCLUSIONS: This detailed compilation of studies from different parts of Asia, draws attention to Asian patients' experiences of IBS.

12 Guideline Guidelines on the irritable bowel syndrome: mechanisms and practical management. 2007

Spiller, R / Aziz, Q / Creed, F / Emmanuel, A / Houghton, L / Hungin, P / Jones, R / Kumar, D / Rubin, G / Trudgill, N / Whorwell, P / Anonymous911306. ·Wolfson Digestive Diseases Centre, University of Nottingham, Nottingham, UK. robin.spiller@nottingham.ac.uk · ·Gut · Pubmed #17488783.

ABSTRACT: BACKGROUND: IBS affects 5-11% of the population of most countries. Prevalence peaks in the third and fourth decades, with a female predominance. AIM: To provide a guide for the assessment and management of adult patients with irritable bowel syndrome. METHODS: Members of the Clinical Services Committee of The British Society of Gastroenterology were allocated particular areas to produce review documents. Literature searching included systematic searches using electronic databases such as Pubmed, EMBASE, MEDLINE, Web of Science, and Cochrane databases and extensive personal reference databases. RESULTS: Patients can usefully be classified by predominant bowel habit. Few investigations are needed except when diarrhoea is a prominent feature. Alarm features may warrant further investigation. Adverse psychological features and somatisation are often present. Ascertaining the patients' concerns and explaining symptoms in simple terms improves outcome. IBS is a heterogeneous condition with a range of treatments, each of which benefits a small proportion of patients. Treatment of associated anxiety and depression often improves bowel and other symptoms. Randomised placebo controlled trials show benefit as follows: cognitive behavioural therapy and psychodynamic interpersonal therapy improve coping; hypnotherapy benefits global symptoms in otherwise refractory patients; antispasmodics and tricyclic antidepressants improve pain; ispaghula improves pain and bowel habit; 5-HT(3) antagonists improve global symptoms, diarrhoea, and pain but may rarely cause unexplained colitis; 5-HT(4) agonists improve global symptoms, constipation, and bloating; selective serotonin reuptake inhibitors improve global symptoms. CONCLUSIONS: Better ways of identifying which patients will respond to specific treatments are urgently needed.

13 Editorial Possible therapeutic role of IgE blockade in irritable bowel syndrome. 2016

Magen, Eli / Chikovani, Tinatin. ·Eli Magen, Medicine C Department, Allergy and Clinical Immunology Unit, Barzilai Medical Center, Ben Gurion University of Negev, Ashkelon 78100, Israel. ·World J Gastroenterol · Pubmed #27920467.

ABSTRACT: Omalizumab is a humanized monoclonal antibody that binds to the high-affinity type-I IgE Fc receptors on mast cells (MCs) and basophils, inhibiting the IgE immune pathway. Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder, and dysregulation of the immune system likely contributes to its etiology and/or symptomatology. Colonic biopsies from patients with IBS demonstrate considerable increase in the number of degranulating MCs releasing histamine in proximity to nerves, and this event may underlie the common IBS symptom of abdominal pain. Pharmacologic control of MC activation and mediator release is a current area of active interest in the field of IBS research. Recently, we and Pearson et al described 2 cases of patients with IBS with diarrhea (IBS-D) showing positive clinical response to omalizumab. In both cases, the female patients had severe, long-lasting IBS-D and achieved an almost complete resolution of IBS symptoms. Both patients were also able to discontinue all IBS medications after commencing the anti-IgE therapy. For both patients, the omalizumab treatment showed a relatively rapid onset of action, resembling the efficacy observed in and previously reported for patients with chronic spontaneous urticaria. In this Editorial, we discuss the possible biological mechanisms that may underlie the clinical efficacy of omalizumab in IBS. We suggest that there is a need for a well-designed prospective study to investigate the therapeutic effects of anti-IgE in IBS.

14 Editorial A definitive blood test for post-infectious irritable bowel syndrome? 2016

Barlow, Gillian M / Rezaie, Ali / Lin, Eugenia / Pimentel, Mark. ·a GI Motility Program , Cedars-Sinai Medical Center , Los Angeles , CA , USA. ·Expert Rev Gastroenterol Hepatol · Pubmed #27682513.

ABSTRACT: -- No abstract --

15 Editorial Irritable bowel syndrome, dyspepsia and other chronic disorders of gastrointestinal function. 2016

Talley, Nicholas J / Holtmann, Gerald. ·Global Research, University of Newcastle, Newcastle, NSW Nicholas.Talley@newcastle.edu.au. · University of Queensland, Brisbane, QLD. ·Med J Aust · Pubmed #27681970.

ABSTRACT: -- No abstract --

16 Editorial Dietary therapy for irritable bowel syndrome. 2016

Lebwohl, Benjamin / Green, Peter H R. ·Department of Medicine, Celiac Disease Center, Columbia University, New York, NY 10032, USA. · Department of Medicine, Celiac Disease Center, Columbia University, New York, NY 10032, USA pg11@columbia.edu. ·BMJ · Pubmed #27449185.

ABSTRACT: -- No abstract --

17 Editorial Irritable bowel syndrome. 2016

Grayson, Michelle. · ·Nature · Pubmed #27191484.

ABSTRACT: -- No abstract --

18 Editorial Mast Cell May Be the Master Key to Solve the Mystery of Pathogenesis of Irritable Bowel Syndrome. 2016

Yoon, Hyuk. ·Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. ·Gut Liver · Pubmed #27114430.

ABSTRACT: -- No abstract --

19 Editorial Editorial: serotonin and irritable bowel syndrome--reconciling pharmacological effects with basic biology; authors' reply. 2016

Mujagic, Z / Keszthelyi, D / Thijssen, A Y / Jonkers, D M A E / Masclee, A A M. ·Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands. z.mujagic@maastrichtuniversity.nl.; NUTRIM School for Nutrition, and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. z.mujagic@maastrichtuniversity.nl. · Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.; NUTRIM School for Nutrition, and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. ·Aliment Pharmacol Ther · Pubmed #26843337.

ABSTRACT: -- No abstract --

20 Editorial Editorial: serotonin and irritable bowel syndrome--reconciling pharmacological effects with basic biology. 2016

Quigley, E M M. ·Division of Gastroenterology and Hepatology, Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA. equigley@tmhs.org. ·Aliment Pharmacol Ther · Pubmed #26843336.

ABSTRACT: -- No abstract --

21 Editorial Irritable bowel syndrome (IBS) subtypes: Nothing resembles less an IBS than another IBS. 2016

Mearin Manrique, Fermín. ·Gastroenterología, Centro Médico Teknon, España. ·Rev Esp Enferm Dig · Pubmed #26838485.

ABSTRACT: Two new members of "IBS Patient Association" met at a meeting. Feeling somewhat lost, not knowing anybody present, they introduced themselves to each other. After exchanging names, one asks the other - "What's your problem?" The other one answers - "I got constipation that laxatives fail to relieve, and my belly, which is always bloated, sometimes hurts so much that I can´t even leave home". Deeply surprised, the first individual inquires - "What are you doing here then?" "Why, I came to this meeting looking for some help for my irritable colon", she answered. "Irritable colon? That's no irritable colon. Irritable bowel syndrome is what I suffer from, and it's diarrhea that won't let me be; can't stop running to the toilet, and cramps just pop up any time". Now both looked surprised. Both thought they had come to the wrong meeting, and both were on the verge of leaving. Luckily, the Association's secretary showed up and explained that both had IBS.

22 Editorial Is irritable bowel syndrome an infectious disease? 2016

Thompson, John Richard. ·John Richard Thompson, Department of Pharmacy Practice, Lipscomb University College of Pharmacy, One University Park Drive, Nashville, TN 37204, United States. ·World J Gastroenterol · Pubmed #26819502.

ABSTRACT: Irritable bowel syndrome (IBS) is the most common of all gastroenterological diseases. While many mechanisms have been postulated to explain its etiology, no single mechanism entirely explains the heterogeneity of symptoms seen with the various phenotypes of the disease. Recent data from both basic and clinical sciences suggest that underlying infectious disease may provide a unifying hypothesis that better explains the overall symptomatology. The presence of small intestinal bowel overgrowth (SIBO) has been documented in patients with IBS and reductions in SIBO as determined by breath testing correlate with IBS symptom improvement in clinical trials. The incidence of new onset IBS symptoms following acute infectious gastroenteritis also suggests an infectious cause. Alterations in microbiota-host interactions may compromise epithelial barrier integrity, immune function, and the development and function of both central and enteric nervous systems explaining alterations in the brain-gut axis. Clinical evidence from treatment trials with both probiotics and antibiotics also support this etiology. Probiotics appear to restore the imbalance in the microflora and improve IBS-specific quality of life. Antibiotic trials with both neomycin and rifaximin show improvement in global IBS symptoms that correlates with breath test normalization in diarrhea-predominant patients. The treatment response to two weeks of rifaximin is sustained for up to ten weeks and comparable results are seen in symptom reduction with retreatment in patients who develop recurrent symptoms.

23 Editorial Distinguishing Microscopic Colitis From Irritable Bowel Syndrome. 2016

Gudsoorkar, Vineet S / Quigley, Eamonn M M. ·Lynda K. and David M. Center for Digestive Disorders, Division of Gastroenterology and Hepatology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas. ·Clin Gastroenterol Hepatol · Pubmed #26707680.

ABSTRACT: -- No abstract --

24 Editorial Treating Irritable Bowel Syndrome: A Fresh and Minty Approach to an Old Therapy. 2016

Harris, Lucinda A. ·Division of Gastroenterology and Hepatology, Department of Medicine, Mayo College of Medicine, 13400 E. Shea Blvd., Scottsdale, AZ, 85259, USA. Harris.Lucinda@mayo.edu. ·Dig Dis Sci · Pubmed #26689805.

ABSTRACT: -- No abstract --

25 Editorial [Irritable bowel syndrome: the next-to-last that is being investigated]. 2016

Sebastián Domingo, Juan J. ·Consulta de Trastornos Funcionales Digestivos, Servicio de Aparato Digestivo, Hospital Royo Villanova, Zaragoza, España. Electronic address: jjsebastian@salud.aragon.es. ·Med Clin (Barc) · Pubmed #26654550.

ABSTRACT: -- No abstract --